What question did this study set out to answer?

To evaluate the effects of ivosidenib in patients with IDH-mutant WHO grade 4 astrocytomas.

February 19, 2026

Ivosidenib treatment in IDH-mutant WHO grade 4 astrocytomas: illustrative case.

Key Points

To evaluate the effects of ivosidenib in patients with IDH-mutant WHO grade 4 astrocytomas.
Reported off-label use of ivosidenib in a clinical case.
Referenced findings from the INDIGO trial regarding low-grade gliomas.
Discussed the need for further studies on high-grade gliomas.
Efficacy of ivosidenib in low-grade gliomas established, but effects on high-grade gliomas remain uncertain.
Further research required to determine impacts on overall and progression-free survival.

Abstract

Here the authors report the effects of the off-label use of ivosidenib. The INDIGO trial published evidence of efficacy in using an IDH inhibitor for low-grade gliomas. The role of these drugs in high-grade IDH-mutant gliomas is currently unknown. Further studies are needed to assess their impact on overall and progression-free survival. https://thejns.org/doi/10.3171/CASE25572.

Ivosidenib treatment in IDH-mutant WHO grade 4 astrocytomas: illustrative case.

Key Points

Abstract

Cite This Study

Also Consider

Also Consider